Our candidate medicines provide the opportunities to cure and modify diseases, and to address the unmet medical needs of patients and their carers.

Our programmes

Our liver-focused pipeline is currently built around three principal areas of high unmet need: haematology, cardiovascular and rare diseases. We also apply a patient-friendly delivery technology suitable for applications in a variety of disease settings.

SilenceTherapeutics_Pipeline_200403.jpg SilenceTherapeutics_Pipeline_200403.jpg

Please click the programme names below to view our factsheets.

Out-licensed programmes

We have out-licensed our siRNA stabilisation chemistry technology (AtuRNAiTM) to Quark Pharmaceuticals, who have progressed drug candidates that use this technology in late-stage clinical trials.

_PipelineMaster_v18 [CTA approved]-02.png _PipelineMaster_v18 [CTA approved]-04.png

Please click the licensee programme names below to view our factsheets.

  • pipeline-logo1.png
  • pipeline-logo2.png